CD38 has been found to express in many hematological malignancies, including multiple myeloma (MM), ALL, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML), making it an attractive target for immunotherapy.[24] In addition, CD38 is regularly and stably expressed at high levels in tumor cells of adult and pediatric patients with T‐ALL.[25] Daratumumab, a monoclonal antibody (mAb) targeting CD38, which was approved by the FDA in 2015 to treat MM, has shown encouraging results for the treatment of T‐ALL in preclinical studies. This evidence concerns the gene CD38 and B-cell chronic lymphocytic leukemia.